Trial reportBlood2017
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.
2 registry-linked trialsOpen access · bronzeAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 691 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
691citing papers in PubMed, 2 pooled it
43.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor-modified Autologous T Cells (CART19) in Patients with Relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma. a Dose Escalation, Open-label, Phase I Study.
NCT07695012 early_phase1recruitingnot on this mapstarted 2026, after this paper: background citation
A Pilot, Single-Arm, Open-Label Feasibility Study of Autologous Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Pediatric and Young Adult Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL)
Who cites it
691 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,083 citations in OpenAlex.
- Association of Ferritin Levels With Cytokine Release Syndrome in CAR T-Cell Therapy: A Systematic Review and Meta-Analysis.Cancer medicine · 2026Pooled it
- A meta-analysis to assess the risk of bleeding and thrombosis following chimeric antigen receptor T-cell therapy: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy.Journal of thrombosis and haemostasis : JTH · 2024Pooled it
- Reprogramming engineered autologous T cells to overcome resistance in patients with Merkel cell carcinoma.Science translational medicine · 2026Trial
- Efficacy and safety of a novel CD19, CD22 dual-targeted fully human loop bi-CAR-T for the treatment of relapsed/refractory B cell non-Hodgkin lymphoma.Journal of translational medicine · 2025Trial
- Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia.Blood advances · 2025Trial
- Research trends and hotspots of CAR-T cell therapy for acute lymphoblastic leukemia: A bibliometric analysis.Human vaccines & immunotherapeutics · 2026Article
- Bridging therapy in pediatric and AYA patients under 25 years with relapsed/refractory B-ALL undergoing anti-CD19 CAR-T therapy: a multicenter retrospective study by the Spanish group GETH-TC.Bone marrow transplantation · 2026Article
- Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.Signal transduction and targeted therapy · 2026Review
- Clinical characteristics, treatment and prognosis of nivolumab induced cytokine release syndrome.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Neural-tumor interactions: bidirectional regulatory mechanisms and nervous system-targeted tumor therapeutic strategies.Biomarker research · 2026Review
- Chimeric antigen receptor T-cell therapy and cardiovascular outcomes in US Medicare beneficiaries.European heart journal · 2026Article
- Endothelial Injury as a Potential Contributor to Cardiovascular Toxicity in Hematologic Malignancies.Diseases (Basel, Switzerland) · 2026Review
- CRS and ICANS: Early detection and personalized management.Blood research · 2026Review
- Predictive Models for Toxicities after CAR T-cell Therapy: Challenges and Opportunities.Blood cancer discovery · 2026Review
- IMMPACT-MM: Insights into Multiple Myeloma Patient Outcomes following Early-Line Cilta-cel Treatment.Oncology and therapy · 2026Article
- A bispecific CD3×CD19 antibody for systemic lupus erythematosus: a phase 1 trial.Nature medicine · 2026Article
- Human biomarker navigator.iMeta · 2026Review
- The New Cardio-Oncology Frontier in Hematologic Cancers: Cardiovascular Toxicities of CAR-T Cells and Bispecific T-Cell Engagers.Journal of clinical medicine · 2026Review
- Piggybacking toward Progress for CAR T-Cell Therapy in Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Nanomaterials Drive In Vivo CAR Immune Cells Engineering.Advanced materials (Deerfield Beach, Fla.) · 2026Review
631 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
15 authors at 5 institutions in 2 countries.
Kevin A HayClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.ORCID 0000-0002-9398-2677
Laïla-Aïcha HanafiClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Daniel LiJuno Therapeutics, Seattle, WA.
Juliane GustSeattle Children's Hospital, Seattle, WA.
W Conrad LilesDepartment of Medicine, University of Washington, Seattle, WA.ORCID 0000-0002-1075-8275
Mark M WurfelDepartment of Medicine, University of Washington, Seattle, WA.
José A LópezDepartment of Medicine, University of Washington, Seattle, WA.ORCID 0000-0002-2550-5131
Junmei ChenBloodworks Northwest, Seattle, WA; and.
Dominic ChungBloodworks Northwest, Seattle, WA; and.
Susanna Harju-BakerDepartment of Medicine, University of Washington, Seattle, WA.ORCID 0000-0001-5151-9361
Sindhu CherianDepartment of Laboratory Medicine, University of Washington, Seattle, WA.
Xueyan ChenDepartment of Laboratory Medicine, University of Washington, Seattle, WA.
Stanley R RiddellClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.ORCID 0000-0002-4688-9920
David G MaloneyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.ORCID 0000-0002-8477-6919
Cameron J TurtleClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.ORCID 0000-0002-4722-4461
University of Washington · USBloodworks Northwest · USFred Hutch Cancer Center · USSeattle Children's Hospital · USUniversity of British Columbia · CA
Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4MCORE--VECTOR PRODUCTIONP30DK056465 · NIDDK · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BERNSTEIN, IRWIN D · 1999 to 2014
$14.9MTargeted therapy of B cell malignances with CAR-T cells of defined compositionR01CA136551 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI JENSEN, MICHAEL C, RIDDELL, STANLEY R. · 2009 to 2018
$5.5MThe Biology of VWF Self-AssociationR01HL137991 · NHLBI · BLOODWORKS · PI CHUNG, DOMINIC W. · 2017 to 2019
$2.0MNCI NIH HHS P30 CA015704NCI NIH HHS R01 CA136551NHLBI NIH HHS R01 HL137991NIDDK NIH HHS P30 DK056465
Abstract
Lymphodepletion chemotherapy followed by infusion of CD19-specific chimeric antigen receptor-modified (CAR) T cells has produced impressive antitumor responses in patients with refractory CD19
Indexed as
Immunotherapy, AdoptiveAdultAgedBiomarkers, TumorBlood Coagulation DisordersCytokinesEndothelial CellsFemaleFeverHematopoiesisHemodynamicsHumansKineticsLymphocyte CountMaleMiddle AgedBiomarkers, TumorCD19-specific chimeric antigen receptorCytokinesReceptors, Antigen, T-Cell
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT05054257ClinicalTrials.gov
NCT07695012ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.